样式: 排序: IF: - GO 导出 标记为已读
-
Current role of topoisomerase I inhibitors for the treatment of mesenchymal malignancies and their potential future use as payload of sarcoma-specific antibody-drug conjugates. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-11-28 Patrick Schöffski,Chao-Chi Wang,Morris Patrick Schöffski,Agnieszka Wozniak
BACKGROUND Topoisomerase I is an enzyme that plays a crucial part in DNA replication and transcription by the relaxation of supercoiled double-stranded DNA. Topoisomerase I inhibitors bind to the topoisomerase I cleavage complex, thereby stabilizing it and preventing the religation of the DNA strands, leading to DNA damage, cell cycle arrest and apoptosis. Various topoisomerase I inhibitors have been
-
Oncolytic activity of Canine Distemper virus in human ductal breast carcinoma cells. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-11-26 Dhwani Jhala,Neelam Nathani,Madhvi Joshi,Amrutlal Patel,Chaitanya G Joshi
Oncolytic virotherapy is a novel strategy for cancer treatment in humans and companion animals. Canine distemper virus (CDV) is known to induce apoptosis in tumor cells, thus serving as a potential candidate for oncolytic therapy. However, the mechanism of viral oncolytic activity is less studied and varies depending on the type of cancer and cell lines. In the present study, the susceptibility of
-
COVID-19 in patients with active - higher inflammatory activity predicts poor outcome. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-11-15 Maria Madeleine Rüthrich,Yascha Khodamoradi,Julia Lanznaster,Melanie Stecher,Lukas Tometten,Florian Voit,Carolin E M Koll,Stefan Borgmann,Jörg Janne Vehreschild,Björn-Erik Ole Jensen,Frank Hanses,Clemens Giessen-Jung,Kai Wille,Marie von Lilienfeld-Toal,Gernot Beutel
INTRODUCTION Active malignancies have been identified as an independent risk-factor for severity and mortality in COVID-19. However, direct comparisons between SARS-CoV-2 infected patients with active (acP) and non-active cancers (n-acP) remain scarce. PATIENTS AND METHODS We retrospectively analyzed a cohort of cancer patients with PCR confirmed SARS-CoV-2 infection, enrolled from 03/16/2020 to 07/31/2021
-
Clinical features, treatment modalities and outcomes of elderly thymoma patients: A propensity-matched study based on the SEER database. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-11-14 Zhidong Wang,Cheng Gong,Youpu Zhang,Min Wanga,Ce Chao,Yongxiang Qian,Bin Wang,Dongmei Di
INTRODUCTION Thymoma is a common mediastinal tumor, but few studies have been performed in thymoma patients 80 years or older. This study aimed to analyze the clinical features, treatment modalities and survival outcomes of thymoma patients at least 80 years old and compare these features to those of patients younger than 80 years old. METHOD Data from thymoma patients in the Surveillance, Epidemiology
-
Selective COX-2 inhibitor is beneficial in suppressing chronic postoperative pain in esophageal cancer patients and may prolong patient survival. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-11-14 Xiaoqing Fan,Shan Wang,Kunyun Pan,Delong Wang,Ruiting Wang
INTRODUCTION Chronic postsurgical pain (CPSP) is a common complication after surgical procedures. Radical resection of esophageal cancer is a complex procedure, one of the most extensive and traumatic surgical procedures in oncological surgery, and the incidence of postoperative chronic pain is high, seriously affecting patients' postoperative recovery. Therefore, this study aims to investigate the
-
Effects of Breast-Conserving Surgery and Mastectomy on the Survival of Patients with Early-stage (T1-2N0-1M0) HER2-Positive Breast Cancer: A Propensity Score-Matched Analysis. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-11-06 Qiaohui Zhan,Xuye Zhao,Guifeng Zheng,Jiahui Liu,Songling Wu,Jiawen Huang,Liuwen Yu,Fangmeng Fu
INTRODUCTION Although breast-conserving therapy (BCT) promises at least a similar survival rate for patients with early breast cancer compared with mastectomy, its efficacy in patients with human epidermal growth factor receptor 2 (HER2)-positive tumors remains unclear. Therefore, we conducted this study to explore differential effects of BCT and mastectomy on survival outcomes of patients with early-stage
-
Clinicopathological Features and Survival Trends of Non-Epithelial Ovarian Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-10-19 Chunxiao Zhang,Xiaowei Xi
INTRODUCTION Owing to their low incidence, no reliable statistics about prognostication derived from large sample sizes have been reported of malignant ovarian germ cell tumors (MOGCTs) and sex cord-stromal tumors (SCSTs). The present study aimed to investigate the clinicopathological prognostic factors and the survival trends of MOGCTs and SCSTs. MATERIALS AND METHODS Patients with MOGCTs and SCSTs
-
Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-10-16 Hayder Saeed,Jose Sandoval-Sus,Franco Castillo-Tokumori,Ning Dong,Jerrin Joy Pullukkara,Stephanie Boisclair,Amanda Brahim,Damaal Walker,Sanjay Bridgellal,Ling Zhang,Lubomir Sokol
INTRODUCTION Adult T-cell leukemia lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection. Despite its poor prognosis, there is no standard therapy for ATLL due to its low incidence and the disease affecting only endemic geographical clusters. METHODS A retrospective evaluation of patients with the diagnosis of ATLL at Moffitt Cancer
-
Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-10-12 Stefan Munker,Daniel Roessler,Osman Öcal,Najib Ben-Khaled,Kathrin Bernhart,Liangtao Ye,Ignazio Piseddu,Jakob Vielhauer,Florian P Reiter,Isaac Rodriguez,Jens Ricke,Andreas Teufel,Enrico De Toni,Max Seidensticker,Maximilian Niyazi,Stefanie Corradini
INTRODUCTION Immunotherapy has been established as the standard treatment option for patients with advanced hepatocellular carcinoma (aHCC). Despite the increased efficacy, disease progression occurs in a relevant proportion of patients even after an objective response. Combination concepts with locoregional therapy are currently under investigation for hepatic disease but are also in discussion for
-
[Therapiesteuerung in der Hämatologie und Onkologie]. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-09-25 C Benedikt Westphalen,Bernd J Krause,Markus Schuler,Sara Y Brucker,Andreas Hartkopf,Leo Rasche,Susanne Saußele,Bernhard Wörmann,Josef Hecken,Martin Danner
Die diesjährige Frühjahrstagung der DGHO (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V.) stand unter der Überschrift «Herausforderungen in der Onkologie - personalisierte Therapiesteuerung». Über drei Themenkomplexe hinweg wurden aktuelle Möglichkeiten und Perspektiven der Therapiesteuerung in der Onkologie hinsichtlich «Methoden», gelungenen «Beispielen» sowie der «Umsetzung
-
Key Prognostic Factors Create a Composite Risk Score to Stratify Patients into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of the CORRECT and CONSIGN Trials. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-08-22 Linda Katharina Zöhrlaut,Meinolf Karthaus,Ursula Vehling-Kaiser,Lukas von Kunhardt,Sebastian Stintzing,Volker Heinemann,Jobst C von Einem
INTRODUCTION In further-line mCRC treatment, median progression-free survival (PFS) is rather short, and many patients do not benefit from any antitumor treatment and should therefore be treated according to best-supportive care. A risk score based on standard laboratory values using markers of tumor inflammation aims to define a patient cohort with high treatment benefit and might offer insights into
-
No Survival Differences among Germ-Cell Cancer Patients from Urban and Rural Areas. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-08-11 Dennis Hoch,Simon Helnwein,Davide Adrizzone,Anja Lorch,Christian Fankhauser,Thomas Hermanns,George Thalmann,Jörg Beyer
INTRODUCTION Germ-cell cancer (GCC) is curable in the majority of men. However, previous reports have described inferior outcomes in men living in rural as compared to urban residential areas. METHODS We identified all GCC patients treated at two large university hospitals in Zürich and Bern, both in Switzerland, between 2010 and 2020 by retrospective chart review. In 400 patients from Zürich and 274
-
The Leucine-Rich α2-Glycoprotein-1 Levels in Patients with Multiple Myeloma. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-08-01 Murat Kaçmaz,Hamdi Oğuzman
INTRODUCTION Angiogenesis is considered important in the pathogenesis of multiple myeloma (MM), as well as in the targeted treatment of the disease. Leucine-rich α2-glycoprotein 1 (LRG1) is a protein that participates in angiogenesis and its effect on solid organ tumors has been investigated recently. This study aimed to investigate the relationship between MM and LRG1. METHODS The MM patients who
-
Updated International Guidelines for Survivorship Care after Pediatric Cancer: Practice Implications in a German and Austrian Comprehensive Care Network. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-07-28 Judith Gebauer,Katja Baust,Edit Bardi,Desiree Grabow,Gabriele Calminus,Cécile M Ronckers,Thorsten Langer
BACKGROUND Timely diagnosis of treatment-related chronic health conditions in childhood cancer survivors (CCS) may result in reduced long-term morbidity and mortality. Evidence-based guidelines serve as a tool to implement risk-adapted screening examinations in long-term follow-up (LTFU) of CCS. SUMMARY New international LTFU guidelines from the last 3 years have been reviewed and included into a practical
-
Health Economic Aspects of Platelet Concentrates: Comparing Cost and Reimbursement of Pathogen Inactivated and Conventional Platelet Concentrates in a German Comprehensive Cancer Center. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-07-21 Jennifer Bonn,Christoph T Baltin,Viola Osterkamp,Christof Scheid,Udo Holtick,Johannes Irsch,Florian Kron
INTRODUCTION Pathogen inactivation (PI) utilizing amotosalen and UVA light (INTERCEPT® Blood System) is a well-established method for the production of safer platelet concentrates (PCs). While many studies describe clinical and logistical benefits of PI, the implications and potential challenges from a hospital management perspective have not yet been analyzed - health economic analyses considering
-
Assessment and Evaluation of Psychosocial Distress in Outpatients with Cancer at a University Hospital in Germany. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-07-20 Laura Hohmann,Kirsten Merx,Simone Weingaertner,Annette Schreiber,Svetlana Hetjens,Wolf-Karsten Hofmann,Ralf-Dieter Hofheinz,Deniz Gencer
INTRODUCTION Cancer patients (pts) suffer from a significant amount of psychosocial distress related to tumor disease itself or straining treatments. Despite recommendations on how to screen for and to deal with psychosocial distress in cancer pts, data about implementation of psycho-oncological interventions (poi) in outpatient settings of cancer pts are scarce. The aim of this study was to identify
-
Sarcoma Research with Cancer Registry Data: Data and Peculiarities of Germany in the Light of Other Countries. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-06-28 Sylke Ruth Zeissig,Katharina Emrich,Fabian Reinwald,Bernd Kasper,Kees Kleihues-van Tole,Christina Justenhoven,Eva Wardelmann,Peter Hohenberger
INTRODUCTION Sarcomas are documented in population-based and in clinic-associated databases. This study evaluated the status quo regarding the potential and obstacles of cancer registry-based research on sarcomas exemplified by Germany in comparison to similar databases in the US and Europe. Completeness and quality of data are discussed based on statistical analyses of a pooled data set established
-
Curative Polyendocrine Therapy in a 21-year-Old Patient with Endometrial Carcinoma: Case Report and Review of the Literature. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-06-26 Henning Schäffler,Moritz Dimpfl,Fabienne Schochter,Wolfgang Janni,Nikolaus de Gregorio
INTRODUCTION As the numbers of young patients diagnosed with early-stage endometrial carcinoma continue to rise, the question regarding fertility-preserving therapeutic options will increasingly gain significance in the future. CASE PRESENTATION Here, we present the case of a 21-year-old patient diagnosed with symptomatic atypical endometrial hyperplasia. After 4 months of treatment with medroxyprogesterone
-
Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence? Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-06-16 Mohan Hingorani,Hannah Stubley
BACKGROUND The concept of oligometastatic disease (OMD) was first introduced in 1995 by Hellman and Weichselbaum and described as stage of transition between localized and widespread metastatic disease. The presence of OMD in esophagogastric (OG) cancer remains controversial. Historically, most experts believe that OG cancer is systemic disease from the outset. SUMMARY More recently, there is emerging
-
Variable Outcomes of Hepatitis E Infections in Patients with Hemato-Oncologic Diseases. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-06-13 Viktoria Ingwersen,Jörg Hofmann,Marion Muche,Philipp Le Coutre,Thomas Schneider,Corinna Leng,Thomas Burmeister,Georg Maschmeyer,Ulrich Keller,Stefan Schwartz
INTRODUCTION The hepatitis E virus (HEV) represents an important cause of viral hepatitis and could cause chronic infections in immunocompromised patients. However, data about immunocompromised patients other than solid organ transplant recipients are limited. METHODS We identified patients from a laboratory database and retrospectively compiled and analyzed clinical as well as laboratory data in detail
-
Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-06-09 Yuqin Ding,Wenju Mo,Xiaohong Xie,Ouchen Wang,Xiangming He,Shuai Zhao,Xidong Gu,Chenlu Liang,Chengdong Qin,Kaijing Ding,Hongjian Yang,Xiaowen Ding
INTRODUCTION This multicenter, randomized, double-blind, placebo-controlled phase 2 trial compared the efficacy, and safety of adding pyrotinib to trastuzumab, docetaxel, and carboplatin versus placebo, trastuzumab, docetaxel, and carboplatin in Chinese patients with human epidermal receptor 2 (HER2)-positive early or locally advanced breast cancer (ClinicalTrials.gov identifier: NCT03756064). METHODS
-
Total Lymph Node Yield Is Associated with Prolonged Survival after Neoadjuvant Chemotherapy in ypN0 Gastric Cancer Patients. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-06-09 Weikun Li,Xinxin Shao,Fuhai Ma,Bingzhi Wang,Liyan Xue,Haitao Hu,Wenzhe Kang,Jianping Xiong,Yantao Tian
INTRODUCTION Lymph node status after neoadjuvant chemotherapy (NAC) plays the main role in predicting the survival of gastric cancer (GC) patients who underwent curative gastrectomy after NAC. NAC can reduce the number of involved lymph nodes. However, it is unknown whether other variables are associated with the survival outcomes for ypN0 GC patients. It is unknown whether lymph node yield (LNY) has
-
Management of Aortoesophageal Fistula in a Palliative Patient with Non-Small-Cell Lung Cancer: A Case Report. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-05-30 Kathrin Adler,Ruben Evertz,Albrecht Neesse,Lorenz Biggemann,Tobias R Overbeck
INTRODUCTION Aortoesophageal fistulas are a rare but life-threatening complication in patients with thoracic malignancies. CASE PRESENTATION We describe a case of a 55-year-old female patient with metastatic non-small-cell lung cancer. Due to esophageal tumor compression, a fully covered self-expanding metal stent (fcSEMS) had been deployed in the esophagus several months before. The patient was subsequently
-
Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-05-09 Jule Cecilia Artzenroth,Joseph Tintelnot,Georg Martin Haag,Eray Gökkurt,Johann Steffens,Alexander Stein
INTRODUCTION Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted therapy may be a suitable treatment for selected patients, but its efficacy remains elusive. CASE PRESENTATION Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant
-
Early detection of pancreatic cancer Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-04-25 Jérôme Schwingel, Miriam Decker, Lisa Schneider, Carsten Johannes Stürmer, Manfred P. Lutz
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is increasingly common. Screening for pancreatic cancer is not well established but might increase the chance of detection in the early stages. Summary: We conducted a literature search to summarize current recommendations and to give an overview of patient groups that may benefit from screening. In the general population
-
Osimertinib: Hohe Wirksamkeit im Zentralnervensystem Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-04-24
Oncol Res Treat 2023;46:215–215
-
Multiples Myelom: Langzeitergebnisse der MAIA-Studie Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-04-24
Oncol Res Treat 2023;46:216–218
-
-
-
-
-
Identification and validation of CCNA2 and CCNE2 as potential biomarkers in small cell lung cancer Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-04-14 Xiangxin Zhang, Liu Yang, Bing Huang, Jiangwen Yin, Yutao Wei
Introduction: Small cell lung cancer (SCLC) is a special type of lung cancer sensitive to radiotherapy and chemotherapy but is prone to drug resistance and recurrence and has a very poor prognosis. This study aimed to explore the potential biomarkers and therapeutic targets for SCLC. Methods: After batch normalization of GSE40275, GSE1037, and GSE44447 datasets, R was used to screen SCLC's differentially
-
Early versus delayed tumor specific therapy and survival in patients with lung cancer: a retrospective study Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-04-13 Rike Geiken-Weinstock, Anna K.L. Reyners, Frank Griesinger, Burkhard Joerg Otremba, Michael Hoheisel, Jörg Bäsecke
Introduction: The timing of tumor specific palliative therapy and its influence on the survival of patients with stage IV lung cancer remains unclear. Methods: 375 patients with stage IV lung cancer who experienced an early or delayed therapy (early or delayed therapy group; TG) were investigated using histology and ECOG performance score-related (ECOG-PS) subgroups. Kaplan-Meier and Cox regression
-
-
-
Quality measurement for soft tissue sarcomas in Germany – first results of the Certified Sarcoma Centres Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-31 Johannes Rückher, Ellen Grießhammer, Thomas Langer, Gregor Wenzel, Martin Utzig, Peter Hohenberger, Lars H. Lindner, Jens Jakob, Simone Wesselmann
Introduction: Soft tissue sarcomas (STS) are rare diseases. A high level of standardization and centralisation was lacking in Germany until 2018. Methods: By developing an evidence-based guideline and a certification system for sarcoma centres, foundations for structured, guideline-based and centralised sarcoma care were defined. First results of the certified Sarcoma Centres are presented. Results:
-
Changes In Tumor Immune Microenvironment After Radiotherapy Resistance In Colorectal Cancer: a Narrative Review Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-22 Chao Wang, meng yuan, yongjian gao, ruizhi hou, Defeng Song, Ye Feng
Background: Colorectal cancer (CRC) is a common digestive tract malignancy with high incidence and mortality rates. Radiotherapy is the most common anti-tumor therapeutic regime and is frequently used for treating CRC, especially rectal cancer. However, radiotherapy can lead to tumor resistance to treatment. While previous research on radiotherapy resistance in CRC has mostly focused on the tumor itself
-
Association between resting heart rate and oncological outcomes in patients with early-stage cervical cancer who have undergone radical hysterectomy with pelvic lymphadenectomy Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-06 Kriengsak Dhanaworavibul, Kittinun Leetanaporn, Panote Wattanapaisal, Kittiya Deevongkij, Chutinun Leelarujijaroen, Jitti Hanprasertpong
Introduction: A few studies have explored the association of resting heart rate (RHR) with mortality and/or other oncological outcomes in patients with specific cancers such as breast, colorectal, and lung cancer. This study aimed to evaluate the association between the RHR and oncological outcomes in patients with early-stage cervical cancer (CC) who underwent radical surgical resection. Methods:
-
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-07
Introduction: Despite major advances in surveillance and management, advanced cholangiocarcinoma (CCA) still carries a dismal prognosis. In recent years, several actionable genomic alterations in pancreatobiliary malignancies have been identified. For instance, homologous recombination deficiency (HRD) has been considered a predictive biomarker of clinical response to platinum and poly (ADP-ribose)
-
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-07
Introduction: Despite major advances in surveillance and management, advanced cholangiocarcinoma (CCA) still carries a dismal prognosis. In recent years, several actionable genomic alterations in pancreatobiliary malignancies have been identified. For instance, homologous recombination deficiency (HRD) has been considered a predictive biomarker of clinical response to platinum and poly (ADP-ribose)
-
Association between resting heart rate and oncological outcomes in patients with early-stage cervical cancer who have undergone radical hysterectomy with pelvic lymphadenectomy Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-06
Introduction: A few studies have explored the association of resting heart rate (RHR) with mortality and/or other oncological outcomes in patients with specific cancers such as breast, colorectal, and lung cancer. This study aimed to evaluate the association between the RHR and oncological outcomes in patients with early-stage cervical cancer (CC) who underwent radical surgical resection. Methods:
-
Melflufen: Therapieoptionen beim Multiplen Myelom Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-03
Oncol Res Treat 2023;46:125–125
-
-
Melflufen: Therapieoptionen beim Multiplen Myelom Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-03-03
Oncol Res Treat 2023;46:125–125
-
-
High in-hospital mortality in SARS-CoV-2 infected patients with active cancer disease during Omicron phase of the pandemic – Insights from the CORONA Germany Study Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-23
Introduction: SARS-CoV-2 infected patients with cancer have a worse outcome including a significant higher mortality, compared to non-cancer patients. However, limited data are available regarding in-hospital mortality during the Omicron phase of the pandemic. Therefore, the aim of the study was the comparison of mortality in patients with history of cancer and patients with active cancer disease during
-
High in-hospital mortality in SARS-CoV-2 infected patients with active cancer disease during Omicron phase of the pandemic – Insights from the CORONA Germany Study Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-23
Introduction: SARS-CoV-2 infected patients with cancer have a worse outcome including a significant higher mortality, compared to non-cancer patients. However, limited data are available regarding in-hospital mortality during the Omicron phase of the pandemic. Therefore, the aim of the study was the comparison of mortality in patients with history of cancer and patients with active cancer disease during
-
High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-23 Francis Maren Konermann,Nele Gessler,Peter Wohlmuth,Juergen Behr,Johannes Feldhege,Christian Gloeckner,Melanie A Gunawardene,Klaus R Herrlinger,Thomas Hoelting,Ulrich-Frank Pape,Niels Reinmuth,Axel Stang,Sara Sheikhzadeh,Dirk Arnold,Claas Wesseler
INTRODUCTION SARS-CoV-2 infected patients with cancer have a worse outcome including a significant higher mortality, compared to non-cancer patients. However, limited data are available regarding in-hospital mortality during the Omicron phase of the pandemic. Therefore, the aim of the study was the comparison of mortality in patients with history of cancer and patients with active cancer disease during
-
Patterns of care and survival in cancer patients with brain metastases receiving immune checkpoint inhibitors Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-15
Introduction: Immune checkpoint inhibitors (ICI) have become a mainstay of treatment for different cancer types. The purpose of this study was to evaluate patterns of care and overall survival after diagnosis of brain metastases in patients managed with ICI as component of care. Methods: Retrospective cohort study. Fifty patients were included (34 with brain metastases at first cancer diagnosis, 16
-
Patterns of Care and Survival in Cancer Patients with Brain Metastases Receiving Immune Checkpoint Inhibitors. Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-15 Carsten Nieder,Bård Mannsåker,Luka Stanisavljevic,Ellinor Haukland
INTRODUCTION Immune checkpoint inhibitors (ICIs) have become a mainstay of treatment for different cancer types. The purpose of this study was to evaluate patterns of care and overall survival (OS) after diagnosis of brain metastases in patients managed with ICI as component of care. METHODS This was a retrospective cohort study. Fifty patients were included (34 with brain metastases at first cancer
-
Patterns of care and survival in cancer patients with brain metastases receiving immune checkpoint inhibitors Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-15
Introduction: Immune checkpoint inhibitors (ICI) have become a mainstay of treatment for different cancer types. The purpose of this study was to evaluate patterns of care and overall survival after diagnosis of brain metastases in patients managed with ICI as component of care. Methods: Retrospective cohort study. Fifty patients were included (34 with brain metastases at first cancer diagnosis, 16
-
Expert Report on Immune Thrombocytopenia - Current Diagnostics and Treatment Recommendations from an Expert Group from Austria, Germany, and Switzerland Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-14 Axel Matzdorff, Sonja R. Alesci, Johanna Gebhart, Susanne Holzhauer, Marie Luise Hütter-Krönke, Thomas Kühne, Oliver Meyer, Helmut Ostermann, Ingrid Pabinger, Mathias Rummel, Ulrich J. Sachs, Thomas Stauch, Karolin Trautmann-Grill, Bernhard Wörmann
no Abstract
-
Expert Report on Immune Thrombocytopenia - Current Diagnostics and Treatment Recommendations from an Expert Group from Austria, Germany, and Switzerland Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-14
no Abstract
-
Oncology in Europe Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-13 Florian Lordick, Sylvie Lorenzen, Ralf-Dieter Hofheinz
usually not provided for an editorial
-
Oncology in Europe Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-13
usually not provided for an editorial
-
Circulating glypican-4 is a predictor of 24-month overall survival in metastatic breast cancer Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-07 Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Tobias Dechow, Thomas Decker
Background objective: Endocrine treatment combined with CDK4/6 inhibitors is the preferred treatment strategy in patients presenting with ER-positive/HER2-negative breast cancer, but the clinical course remains highly variable among individual patients. There is an unmet need for prognostic or predictive biomarkers in this important group of patients. Recently, we have identified circulating glypican-4
-
Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-08 Michael Konrad Stahl, Sebastian Willy Ertl, Pouneh Engelmeyer, Hans-Christoph Heuer, Daniel Christian Christoph
Because of their individual vulnerabilities, treatment decisions for older patients can be difficult. Geriatric assessment (GA) may help to select patients for systemic treatment, but its value is still unproven. Older cancer patients (≥65 years of age) with and without complex GA followed by discussion in the geriatric-oncologic conference, who had been treated in palliative intention with standard
-
Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-08
Because of their individual vulnerabilities, treatment decisions for older patients can be difficult. Geriatric assessment (GA) may help to select patients for systemic treatment, but its value is still unproven. Older cancer patients (≥65 years of age) with and without complex GA followed by discussion in the geriatric-oncologic conference, who had been treated in palliative intention with standard
-
Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-07
Introduction: Endocrine treatment combined with CDK4/6 inhibitors is the preferred treatment strategy in patients presenting with ER-positive/HER2-negative breast cancer, but the clinical course remains highly variable among individual patients. There is an unmet need for prognostic or predictive biomarkers in this important group of patients. Recently, we have identified circulating glypican-4 (GPC4)
-
Hochrisiko-MDS: Therapeutischer Ansatzpunkt Immunsystem Oncol. Res. Treat. (IF 2.4) Pub Date : 2023-02-01
Oncol Res Treat 2023;46:50–51